Xinan Wang

11PUBLICATIONS
199CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityPredictive and prognostic markersDiscourse and pragmatics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 18, 2026
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco.

|Dec 21, 2025
Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer.

Xinan Wang, Biagio Ricciuti, Arielle Elkrief

|Sep 04, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8+ and PD-1+ Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors.

Joao V Alessi, James R Lindsay, Anita Giobbie-Hurder

|Aug 27, 2025
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.

Federica Pecci, Hui Li, Alessandro Di Federico

|Apr 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.

Federica Pecci, Rohit Thummalapalli, Stephanie L Alden

|Apr 02, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.

Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti

Pageof 2

Frequent Collaborators

8 joint publications

Biagio Ricciuti

7 joint publications

Mark M Awad

7 joint publications

Alessandro Di Federico

5 joint publications

Joao V Alessi